

Polish Pharmacoeconomic Society activities' review 2/2015

Monika Szkultecka-Dębek *Roche Polska Sp. z o.o*

The 13th International Conference of the Polish Society for Pharmacoeconomics was organized in December 2015 and it was dedicated to "Pharmacoeconomics in Public Health". The conference objective was to address public health issues to multidisciplinary stakeholders such as physicians, pharmacists, economists, lawyers, health managers and public health professionals.

The topics discussed during the sessions chaired by Anna Zawada, prof Karina Jahnz-Różyk, Joanna Lis, Prof Maciej Niewada and prof Marcin Czech were as follows:

- The Agency for Health Technology Assessment and Tariff System Session: Focused on HTA, the AHTA-Pol's commitment and European cooperation for HTA. In this session Wojciech Matusewicz presented a summary of current activities of the Agency and Wojciech Wysoczański provided an update on HTA Guidelines. European cooperation in the field of HTA, the AHTA-Pol's commitment was presented by Anna Zawada and Gabriela Ofierska – Sujkowska shared information about Agency's activities and their extension in the context of the recent change in the Agency's name.

- Personalized medicine and personalized healthcare in Public Health. This session was opened by prof Zbigniew Gaciong's presentation about history, clinic, ethics, subjectivity of the patient. It was continued by prof Jacek Jassem who shared current situation and perspectives on how Personalized Medicine is applied in oncology. Adam Fronczak analyzed the place for the personalized medicine in the public health system and Julian Palacios from Spain presented a new tool for biologic drug monitoring. Pharmacoeconomics in public health in selected European countries and examples from different countries were discussed.

QALY: Pros and Cons session with David Danko and Maciej Niewada -discussion.

Real World Evidence in pharmacoeconomics and outcomes research – a tool for the public health. This session started with prof Dorota Cianciara presenting RWE in the light of the new law on public health followed by examples of using RWE in medical decision making process in different countries by Karel Kostev and in Russia by prof Pavel Vorobjev. A registry example of acute coronary syndromes as a source of information in Polish cardiology was presented.

by prof Marek Gierlotka. Marta Banaszczyk-Ruś shared experience on the new tool (Google Flu Trends™) for monitoring morbidity associated with flu and to what extent we can use it to evaluate resources consumption.

The last session was dedicated to original papers and update on activities of the Polish Pharmacoeconomic Association Sections activities. David Brindley's presentation was dedicated to establishing good authentication practice (GAP) in secondary care to protect against falsified medicines and improve patient safety in Poland.

The Therapeutic Programs, Pharmaceutical Care and Pharmaceutical Law Section (TPPCPL) presented 2015 activities summary and plans for 2016. The Section members work intensively on a pricing lexicon and continue to analyze adverse events costs based on therapeutic programs examples, an activity which started in the past years.

The Quality of Life Section continue working on the QoL lexicon as the next step to the QoL Dictionary in order to provide more detailed explanation to QoL terms in Polish.

The conference was preceded by two workshops delivered by ARCANA Institute.

One was dedicated to Indirect comparisons and the estimation of the health effect basing on indirect data with special focus on methodology and verification of reliability of the model.

The other one was a discussion about the principle of equal treatment of entities in the process of making reimbursement decisions. Looking into who will lose and who will benefit. ■